DRRX Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -222.37% compared to Durect's net margin of -87.96%. Durect's return on equity of -195.11% beat Fortress Biotech's return on equity of --.

Durect has a consensus price target of $6.75, signalling upside risk potential of 837.5%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 922.22%. Given that Fortress Biotech has higher upside potential than Durect, analysts believe Fortress Biotech is more attractive than Durect.

Durect has a beta of 0.883, which suggesting that the stock is 11.665% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Durect has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Durect pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Durect quarterly revenues are $1.9M, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Durect's net income of -$4.3M is higher than Fortress Biotech's net income of -$12.9M. Notably, Durect's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Durect is 10.97x versus 0.42x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -222.37% compared to Durect's net margin of -49.65%. Durect's return on equity of -195.11% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Durect has a consensus price target of $6.75, signalling upside risk potential of 837.5%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Durect has higher upside potential than NovaBay Pharmaceuticals, analysts believe Durect is more attractive than NovaBay Pharmaceuticals.

Durect has a beta of 0.883, which suggesting that the stock is 11.665% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Durect has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Durect pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Durect quarterly revenues are $1.9M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Durect's net income of -$4.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Durect's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Durect is 10.97x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -222.37% compared to Durect's net margin of --. Durect's return on equity of -195.11% beat Palatin Technologies's return on equity of --.

Durect has a consensus price target of $6.75, signalling upside risk potential of 837.5%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Durect, analysts believe Palatin Technologies is more attractive than Durect.

Durect has a beta of 0.883, which suggesting that the stock is 11.665% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Durect has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Durect pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Durect quarterly revenues are $1.9M, which are larger than Palatin Technologies quarterly revenues of --. Durect's net income of -$4.3M is higher than Palatin Technologies's net income of --. Notably, Durect's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Durect is 10.97x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -222.37% compared to Durect's net margin of -18.58%. Durect's return on equity of -195.11% beat Retractable Technologies's return on equity of -16.83%.

Durect has a consensus price target of $6.75, signalling upside risk potential of 837.5%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Durect has higher upside potential than Retractable Technologies, analysts believe Durect is more attractive than Retractable Technologies.

Durect has a beta of 0.883, which suggesting that the stock is 11.665% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Durect has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Durect pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Durect quarterly revenues are $1.9M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Durect's net income of -$4.3M is lower than Retractable Technologies's net income of -$1.9M. Notably, Durect's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Durect is 10.97x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.